Britannilactone diacetate

Cat. No.:	HY-N4190	
CAS No.:	1286694-67-4	0
Molecular Formula:	C ₁₉ H ₂₆ O ₆	
Molecular Weight:	350.41	
Target:	NO Synthase	
Pathway:	Immunology/Inflammation	U A
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.	

BIOLOGICAL ACTIV																								
BIOLOGICAL ACTIV	IIY																							
Description	Britanı	۱r	nila	nilactone	ilactone diace	ilactone diacetate (I	nilactone diacetate (1,6-0	ilactone diacetate (1,6-0,0-Dia	ilactone diacetate (1,6-0,0-Diacetylł	nilactone diacetate (1,6-0,0-Diacetylbritar	nilactone diacetate (1,6-0,0-Diacetylbritannilac	ilactone diacetate (1,6-0,0-Diacetylbritannilactone;	ilactone diacetate (1,6-0,0-Diacetylbritannilactone; Com	ilactone diacetate (1,6-0,0-Diacetylbritannilactone; Compoun	ilactone diacetate (1,6-0,0-Diacetylbritannilactone; Compound 2) e	ilactone diacetate (1,6-0,0-Diacetylbritannilactone; Compound 2) exhibit:	ilactone diacetate (1,6-0,0-Diacetylbritannilactone; Compound 2) exhibits pote	ilactone diacetate (1,6-0,0-Diacetylbritannilactone; Compound 2) exhibits potential	ilactone diacetate (1,6-0,0-Diacetylbritannilactone; Compound 2) exhibits potential NO i	ilactone diacetate (1,6-0,0-Diacetylbritannilactone; Compound 2) exhibits potential NO inhib	ilactone diacetate (1,6-0,0-Diacetylbritannilactone; Compound 2) exhibits potential NO inhibition	ilactone diacetate (1,6-0,0-Diacetylbritannilactone; Compound 2) exhibits potential NO inhibition effect	ilactone diacetate (1,6-0,0-Diacetylbritannilactone; Compound 2) exhibits potential NO inhibition effect.	ilactone diacetate (1,6-0,0-Diacetylbritannilactone; Compound 2) exhibits potential NO inhibition effect.
·																								ilactone diacetate exhibits activity against NO production induced by LPS in BV-2 microglial cells with the EC ₅₀ val
	of 6.3 µ	μ	М.	M. Brita	M. Britannilact	M. Britannilactone d	M. Britannilactone diacet	M. Britannilactone diacetate e	M. Britannilactone diacetate exhibits	M. Britannilactone diacetate exhibits a fav	M. Britannilactone diacetate exhibits a favorab	M. Britannilactone diacetate exhibits a favorable blo	M. Britannilactone diacetate exhibits a favorable blood-b	M. Britannilactone diacetate exhibits a favorable blood-brain b	M. Britannilactone diacetate exhibits a favorable blood-brain barrie	M. Britannilactone diacetate exhibits a favorable blood-brain barriers (BBI	M. Britannilactone diacetate exhibits a favorable blood-brain barriers (BBB) per	M. Britannilactone diacetate exhibits a favorable blood-brain barriers (BBB) penetrat	M. Britannilactone diacetate exhibits a favorable blood-brain barriers (BBB) penetration a	M. Britannilactone diacetate exhibits a favorable blood-brain barriers (BBB) penetration and a	M. Britannilactone diacetate exhibits a favorable blood-brain barriers (BBB) penetration and abso	M. Britannilactone diacetate exhibits a favorable blood-brain barriers (BBB) penetration and absorption,	M. Britannilactone diacetate exhibits a favorable blood-brain barriers (BBB) penetration and absorption, distri	M. Britannilactone diacetate exhibits a favorable blood-brain barriers (BBB) penetration and absorption, distributi
	metab	00	lis	lism, ex	lism, excretior	lism, excretion, and	lism, excretion, and toxic	lism, excretion, and toxicity (A	lism, excretion, and toxicity (ADMET	lism, excretion, and toxicity (ADMET) prov	lism, excretion, and toxicity (ADMET) property [[]	lism, excretion, and toxicity (ADMET) property ^[1] .	lism, excretion, and toxicity (ADMET) $property^{[1]}$.	lism, excretion, and toxicity (ADMET) $property^{[1]}$.	lism, excretion, and toxicity (ADMET) property ^[1] .	lism, excretion, and toxicity (ADMET) property ^[1] .	lism, excretion, and toxicity (ADMET) property ^[1] .	lism, excretion, and toxicity (ADMET) property ^[1] .	lism, excretion, and toxicity (ADMET) property ^[1] .	lism, excretion, and toxicity (ADMET) property ^[1] .	lism, excretion, and toxicity (ADMET) property ^[1] .	lism, excretion, and toxicity (ADMET) property ^[1] .	lism, excretion, and toxicity (ADMET) property ^[1] .	lism, excretion, and toxicity (ADMET) property ^[1] .

REFERENCES

[1]. Tang JJ, et al. 1,10-Seco-Eudesmane sesquiterpenoids as a new type of anti-neuroinflammatory agents by suppressing TLR4/NF-κB/MAPK pathways. Eur J Med Chem. 2021 Nov 15;224:113713.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA

=0

Product Data Sheet

